Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma
Antonio Rosato
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorMichela Pivetta
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorCorresponding Author
Anna Parenti
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Fax: +39-049-8072854.
Department of Oncology and Surgical Sciences, Pathology Section, Via Gabelli 61, I-35128 Padova, ItalySearch for more papers by this authorGaetano A. Iaderosa
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Search for more papers by this authorAlessia Zoso
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorGabriella Milan
Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
Search for more papers by this authorSusanna Mandruzzato
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorAlberto Ruol
Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
Search for more papers by this authorGiovanni Zaninotto
Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
Search for more papers by this authorPaola Zanovello
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorAntonio Rosato
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorMichela Pivetta
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorCorresponding Author
Anna Parenti
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Fax: +39-049-8072854.
Department of Oncology and Surgical Sciences, Pathology Section, Via Gabelli 61, I-35128 Padova, ItalySearch for more papers by this authorGaetano A. Iaderosa
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Search for more papers by this authorAlessia Zoso
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorGabriella Milan
Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
Search for more papers by this authorSusanna Mandruzzato
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorAlberto Ruol
Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
Search for more papers by this authorGiovanni Zaninotto
Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
Search for more papers by this authorPaola Zanovello
Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
Istituto Oncologico Veneto, Padova, Italy
Search for more papers by this authorAbstract
We quantified the expression of survivin, both as mRNA in real-time PCR and protein in immunohistochemistry, in tumor samples of 112 patients with esophageal cancer (56 squamous cell carcinomas and 56 adenocarcinomas). Overall survival of squamous cell carcinoma patients with high survivin mRNA levels was significantly less than that of patients with low survivin mRNA levels (p = 0.0033). Distribution pattern of survivin (nuclear vs. cytoplasmic or mixed) was not correlated to survival, while the extent of immunostaining was significantly correlated to survivin mRNA values (p = 0.016) and had prognostic relevance in univariate analysis (p = 0.0012). Cox's proportional-hazard regression model showed that tumor survivin expression in esophageal squamous cell carcinoma was the most important prognostic factor, independent of tumor stage and other histopathological factors, both as mRNA relative value (p = 0.0259) and protein immunostaining (p = 0.0147). In esophageal adenocarcinoma, survivin expression and pattern of distribution had no prognostic relevance. Thus, quantifying survivin expression provides a prognostic marker only for esophageal squamous tumors. © 2006 Wiley-Liss, Inc.
References
- 1 Altieri DC. Survivin and apoptosis control. Adv Cancer Res 2003; 88: 31–52.
- 2 O'Driscoll L, Linehan R, Clynes M. Survivin: role in normal cells and in pathological conditions. Curr Cancer Drug Targets 2003; 3: 131–52.
- 3 Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183–90.
- 4 Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46–54.
- 5 Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002; 4: 317–27.
- 6 Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241–52.
- 7 Paulson TG, Reid BJ. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 2004; 6: 11–16.
- 8
Kato J,
Kuwabara Y,
Mitani M,
Shinoda N,
Sato A,
Toyama T,
Mitsui A,
Nishiwaki T,
Moriyama S,
Kudo J,
Fujii Y.
Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy.
Int J Cancer
2001;
95:
92–5.
10.1002/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9 CAS PubMed Web of Science® Google Scholar
- 9 Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 2002; 87: 883–7.
- 10 Ikeguchi M, Yamaguchi K, Kaibara N. Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol 2003; 24: 40–5.
- 11 Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Stein H, Hopfner M, Germer CT, Scherubl H. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003; 88: 115–19.
- 12 Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 450–64.
- 13 Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005; 3: 1–10.
- 14 Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343–6.
- 15 Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003; 7: 77–86. Discussion 86–7.
- 16 McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004; 64: 1561–9.
- 17 Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005; 114: 509–12.
- 18 Dabrowski A, Filip A, Zgodzinski W, Dabrowska M, Polanska D, Wojcik M, Zinkiewicz K, Wallner G. Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol 2004; 42: 169–72.
- 19 Li YH, Wang C, Meng K, Chen LB, Zhou XJ. Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. World J Gastroenterol 2004; 10: 1984–8.
- 20 Miyachi K, Sasaki K, Onodera S, Taguchi T, Nagamachi M, Kaneko H, Sunagawa M. Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 2003; 6: 217–24.
- 21 Meng H, Lu C, Mabuchi H, Tanigawa N. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 2004; 216: 147–55.
- 22 Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol 2004; 10: 3245–50.
- 23 Piazuelo MB, Haque S, Delgado A, Du JX, Rodriguez F, Correa P. Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol 2004; 17: 62–74.
- 24 van Dekken H, Geelen E, Dinjens WN, Wijnhoven BP, Tilanus HW, Tanke HJ, Rosenberg C. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999; 59: 748–52.
- 25 Taniere P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec JY, Montesano R, Berger F, Hainaut P. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol 2001; 158: 33–40.
- 26 Buskens CJ, Sivula A, van Rees BP, Haglund C, Offerhaus GJ, van Lanschot JJ, Ristimaki A. Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut 2003; 52: 1678–83.
- 27 Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LO, Rath JC, Bock M, Brocker EB, Straten PT, Kampgen E, Becker JC. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23: 884–9.
- 28 Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19.
Citing Literature
